Introduction
Recent advances in gene expression profiling techniques allow for the simultaneous analysis of transcription patterns of literally thousands of genes. 1 These capabilities, in combination with samples carefully selected according to diagnostic criteria, treatment response and final outcome, may lead to the discovery of novel diagnostic and prognostic markers and to a better fundamental understanding of the genetic determinants for treatment resistance. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The power of the microarray approach lies in the numbers: because tens of thousands of genes are analyzed simultaneously and without predetermined bias, novel genes involved in disease processes are being discovered. [19] [20] [21] [22] [23] [24] [25] [26] [27] This knowledge allows investigators to develop not only new diagnostic markers but also prognostic and disease progression markers, ultimately leading to the prospect of patient-tailored therapy.
Several types of microarray platforms, commercialized by different companies (Affymetrix s , Agilent s , Codelink s (GE Healthcare) to name but a few) or produced by facilities of nonprofit organizations (e.g. by the Stanford Functional Genomics Facilities, Stanford University, CA, USA), are available and their number is still increasing. The platform choices differ in probe content, design and deposition technology, as well as labeling and hybridizing protocols. [28] [29] [30] [31] [32] Different probe types include cDNA sequences (usually several hundred base pairs in length), short (25-30 mer) DNA oligonucleotides (up to 16 per gene of interest) or longer (60-80 mer) DNA oligonucleotide probes. The probes can be either contact-spotted using pins or deposited using ink-jet devices (in this manuscript referred to as spotted arrays). Furthermore, oligonucleotides can be synthesized in situ on a quartz wafer (Affymetrix, High Wycombe, UK). Labeling methods vary from in vitro transcribed biotinylated cRNA (stained with streptavidin-phycoerythrin after hybridization) or directly labeled cDNA targets with incorporated fluorescently labeled deoxyribonucleotides. Finally, microarray procedures can be carried out in one color (one labeled target per array, such as used by Affymetrix) or two colors (two separately labeled targets for each array used, for instance, by Agilent Technologies, Palo Alto, CA, USA).
With so many variables in place and moreover thousands of raw data parameters to measure and analyze, it has been realized that standardization and quality guidelines are needed to assure that this powerful tool can fulfill its promises. 33, 34 One of the first and very successful attempts has been the requirements put forward in MIAME (Minimum Information About a Microarray Experiment) by the Microarray Gene Expression Data Society. 35 ,36 MIAME mainly documents information about the experimental design, RNA extraction and labeling techniques as well as array type used. Many journals (all Nature Press journals including Leukemia) now require submission of microarray data to either of two databases emerging as the main public repositories: GEO 
Results and discussion
Handling and initial processing of leukemic cell samples
Leukemic material is usually obtained from peripheral blood or bone marrow. Between drawing the sample and laboratory evaluation, with further processing (freezing, purification or RNA extraction for downstream microarray analyses), a variable length of time may exist, especially within the framework of multi-center studies. 40 As shown recently, blood or bone marrow drawn in sterile tubes with appropriate anticoagulants should be processed within 24 h. 41 Material stored at room temperature for longer periods of time, particularly if sent in polystyrene boxes in the case of multi-center studies, can still yield useful data if used in large classification series. These patient samples and the time until processing should be annotated. Chelating of divalent cations by long storage in ethylenediaminotetraacetic acid could negatively influence the integrity of lymphocytes. 42, 43 However, there are no data on the role of different anticoagulants in gene expression studies. Therefore, no consensus on the usage of a certain anticoagulant has been reached. Most importantly, the same anticoagulant should be used throughout the study.
In most studies, Ficoll density centrifugation is used to isolate the mononuclear cell fraction containing the leukemic cells. The main advantage of Ficoll density centrifugation is to isolate mononuclear cells while granulocytes, erythrocytes, reticulocytes and platelets are removed. In particular, the exclusion of granulocytes is an advantage compared to all other methods, with respect to the 'purity' of gene profiles and the quality of RNA, as it is notoriously difficult to obtain good RNA from granulocytes (U Lehmann, personal communication). The exclusion of reticulocytes reduces the contribution of globin mRNA to the expression profile. However, a reduction of globin mRNA can also be achieved using erythrocyte lysis. 41 An additional advantage of Ficoll is that it can readily be used on thawed material to remove dead cells, resulting in better RNA quality.
The use of PAXgene blood RNA system (PreAnalytiX GmbH, Hembrechtikon, Switzerland) as stabilization reagent offers an advantage over the shipping of non-stabilized samples by direct preservation of RNA. However, for bone marrow samples, it was shown that the PAXgene reagent provided only insufficient protection from pre-analytical alterations for a number of transcripts. 41 In addition, a disadvantage of this approach is the contamination with, for example, large amounts of globinand other erythrocyte-specific mRNAs, which significantly influences the whole gene expression profile owing to its abundance. 44 Although, for instance Affymetrix has developed globin reduction protocols, these are quite time consuming and difficult to implement in large-scale clinical studies. However, globin reduction protocols provide a huge advantage for solid tumors, where the application of Ficoll or other methods of purification (e.g. antibody-based by magnetic activated cell sorter (MACS)) is difficult.
If RNA is not directly prepared (see below), cells can then be frozen, preferentially stepwise in a density below 20 Â 10 6 cells/ ml to assure good recovery upon thawing. In our experience, rapid thawing at 371C produces the best results in terms of recovery of total RNA from the leukemic cells. This is because rapid thawing (until a small clump remains in the ampoule, followed by rapid dilution in medium devoid of dimethyl sulfoxide) leads to the best recovery of leukemic cells.
To purify or not to purify
Before proceeding to RNA extraction, it is important to consider whether to purify the leukemic cell population. Sometimes tumor loads approach 100% and purification obviously is not needed. In most cases, however, tumor loads vary between 30 and 95%. It depends on the question to be answered whether purification is an absolute requirement. To understand signaling pathways, the analysis of a pure cell population is often required. Thus, if tumor loads are below 90% and if one wishes to make statements on the gene expression profile of tumor cells with a statistical confidence of 95%, which is a standard cutoff in most studies, 45 purification is necessary. However, the influence of purification procedures on gene expression has not yet been investigated very extensively in experimental settings. Moreover, molecular features of non-malignant immune cells present in the tumor or leukemia sample at diagnosis may give important information. 46 If there is doubt as to the specificity of genes detected, for example, a T-cell-associated signature in B-precursor acute lymphoblastic leukemia (ALL), an alternative way is to compare the gene expression signatures of unpurified and purified cells in a subset of samples. For classification purposes, purification is often not obligatory, but would certainly improve the quality of the data. One needs to realize that even in classification studies the signature, that is, list of genes that discriminates between different leukemic subcategories, is error-prone and lower tumor loads lead to a larger proportion of falsely identified genes, particularly if the number of samples per class is too low. Proper use of biostatistical tools and an adequate validation are important in this respect. The minimum tumor load that will still lead to correct classification probably depends on several variables, that is, the leukemic subtype in question and this issue should be explored further by future experimentation. We strongly encourage such studies. For now, we recommend that, for classification studies, the tumor load of the samples should be reported.
For most microarray purposes, MACS purification based on markers expressed on the tumor cells, such as CD34, CD19, (B-precursor ALL) or CD7 (T-ALL), is the most appropriate technique to purify leukemic cells. Alternatively, MACS purification via negative selection can be performed with a mixture of antibodies that can deplete all non-leukemic cells (e.g. acute myeloid leukemia (AML)). It is sometimes difficult to reach sufficiently high purity (490%) required for array analyses. 45 As purification by positive selection may stimulate cell surface receptor expression and concurrently alter the gene expression profile, the purification procedure needs to be carried out in the cold to reduce such an effect.
RNA extraction
RNA extraction is very important, as microarray results are directly influenced by the quality of the RNA used. Most investigators currently use two major techniques: TRIzol s (Invitrogen Corp., Carlsbad, CA, USA) and RNeasy (Qiagen, Hilden, Germany) and sometimes TRIzol followed by column purification from the RNeasy kit. Some investigators have used adapted TRIzol extraction methods, with improved quality compared to the original TRIzol methods. Others prefer RNeasy, as it is quick, reproducible and easy to use. The results of a multi-center quality round within the Genomics/Proteomics project of the German Competence Network 'Acute and Chronic Leukemias' demonstrated that both methods work for extracting high-quality RNA in sufficient amounts (Figure 1) . However, as the methods are technically different, it is wise to use only one method within an experimental series. This is illustrated by a series of T-ALL samples from which RNA was extracted either by RNeasy or by TRIzol. Using hierarchical clustering, all TRIzol samples clustered together instead of with the RNeasy extracted samples of the same patients (see Supplementary data). This demonstrates that the RNA extraction method used can have significant influence on the gene expression profile generated. Which of the many methods to isolate RNA is best suited for microarray analyses, especially on large numbers of clinical studies, warrants future study.
The amount of extracted RNA should be quantified by spectrophotometry. The NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) has become popular, as it is capable of measuring nucleic acids in very small volumes, allowing accurate quantification on small amounts of material. The ratio of spectra measured at 260 and 280 nm is very helpful in assessing the purity of RNA and often used as an indicator of RNA quality. However, it is important to consider that the absorption ratio is pH and ionic strengthdependent and should be measured under identical conditions. 47 The RNA 260/280 ratio should ideally be 2.0, but anything above 1.8 is also acceptable.
For quality control (QC), the Agilent Bioanalyzer 2100 has established itself as an important piece of laboratory equipment. Using the 'Lab-on-a-chip' technology, the quality of RNA can be estimated very precisely, again on small amounts of the precious material. Freely available software tools such as Degradometer and RNA Integrity Number (RIN) systems produce userindependent and objective RNA quality metrics. 48, 49 However, this instrument should not been used for quantification purposes as an acceptable precision of quantification can only be obtained in a small range of concentration.
In most studies, poor RNA samples are not being used for further microarray analysis. Our extensive study on RNA quality versus microarray outcome on the Affymetrix platform did not show a correlation between 260/280 ratio and outcome of the array in terms of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 3 0 /5 0 ratio or percentage of genes present, largely because poor RNA samples were not further processed and therefore never yielded a GAPDH result from the array (Figure 2 ). The GAPDH 3 0 /5 0 ratio is a commonly used quality parameter measuring the signal at the 3 0 and 5 0 regions of the GAPD mRNA, which, without degradation of the RNA, should ideally be 1.0. A commonly accepted GAPD ratio is o3.0 (Figure 2) . A similar statement has to be made for 28S:18S rRNA ratios measured using the Agilent Bioanalyzer and the number of well-measured spots on spotted arrays. From our point of view, it is important to consider both the 28S and 18S rRNA peaks and signs of degradation or to use objective metrics such as Degradometer or RIN. Further studies are needed to address systematically the correlation of, for example, RIN numbers and microarray outcome. However, objective RNA quality metrics should be reported as part of the MIAME standards. 35 
RNA labeling and possible amplification
For most microarray systems, standard protocols exist for labeling the RNA or cDNA that is to be hybridized onto the array. The first method typically involves a cDNA reaction to yield a suitable template that can be used by RNA polymerases (most often T7 RNA polymerase) to incorporate labeled nucleotides. Most spotted arrays use the labels Cy3 and Cy5, whereas Affymetrix uses biotinylated nucleotides, which are subsequently stained by phycoerythrin-conjugated streptavidin after hybridization. In some applications, directly labeled RNA is used. This avoids any artifacts that can arise from the (typically fairly linear) amplification by T7 polymerase. The disadvantage is that at least five-to 10-fold more input RNA is required, which may mean that many clinical samples yield insufficient RNA for microarray analysis. Moreover, direct labeling can cause artifacts, regardless of whether or not amplification is being applied. Again, the same labeling method should be used throughout the study. Most suppliers now have protocols that require 1-5 mg of total RNA as starting material. In our experience, starting with amounts much lower than 1 mg for Affymetrix arrays can give good results, but this is unpredictable. Even amounts of 1-2 mg do not always yield sufficient cRNA for hybridization onto an array.
When performing gene expression studies on leukemic samples, in most cases more than 2 mg RNA can be isolated, and amplification schedules, which also take longer and cost more, can readily be avoided, especially when using the Affymetrix system (keep in mind that the Affymetrix standard protocol already includes one step of amplification). Many spotted arrays require more input RNA than Affymetrix arrays; therefore, amplification is more often required. Various amplification protocols using an additional amplification step have been developed that yield sufficient RNA for hybridization. Using, for instance, commercially available amplification kits based on the linear amplification protocol developed by Van Gelder et al., 50 profiles of gene expression using amplified RNA could be confirmed with a high accuracy when re-analyzing the expression of these genes using non-amplified RNA by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). 18 If amplification is applied, it should be performed in all samples using the same protocol and chemistry. Quantitative RT-PCR validation from non-amplified RNA should be performed to test for amplification bias.
Finally, a general recommendation needs to be stated here: as by using microarrays, differential gene expression between samples and not primarily absolute expression values of an individual sample is measured, samples within a study should be treated as identically as possible to avoid technical variation to over-ride biological variation of differential expression. The technical variations should be kept to a minimum and documented in detail.
Technical aspects of hybridization, washing and scanning
Similar to labeling, hybridization is often carried out according to protocols supplied by the manufacturers of those arrays actually used (Agilent, Affymetrix, etc.). Because these protocols can change and therefore real standard protocols do not exist, it is important to document which protocol is used. For spotted arrays, comparative hybridization of two samples labeled with different fluorescent dyes is often performed. We recommend the use of a common RNA standard for all arrays in one study, for example, the Universal Human Reference RNA (Stratagene, Heidelberg, Germany), especially if an enlargement of sample size is intended. For Affymetrix microarrays, established procedures also exist for washing and scanning. For spotted arrays, washing can be performed manually or using an automated system. After scanning, one should check the array for scratches and bubbles and other artifacts.
Data extraction
Every supplier has its own software to translate the fluorescence signal into a value corresponding to the expression of the gene interrogated by the probe. In Affymetrix arrays, several quality parameters should be checked: the above-mentioned 3 0 /5 0 ratio for the housekeeping genes such as GAPD and ACTB, the noise, background, scaling factor and percentage of genes was detected as present. These parameters not only tell the investigator something about the sample in question but also if it can be safely compared to other samples in a given series of experiments. A scaling factor should not differ more than threefold between arrays in order to compare them. Also, in our experience, leukemic samples should have at least 25% of genes present on the latest Affymetrix HG-U133 Plus 2.0 arrays, as well as on the U133A arrays. On U95A arrays, present calls tend to be higher (35-50%). To assess the quality of spotted arrays, it is important to check the homogeneity of hybridization, and to assure a uniformly low hybridization background. In addition, one has to carefully check and optimize the grid alignment and to define parameters for well-measured spots, which can be included in subsequent analyses. Examples are described in recently published studies. 8, 18, 50, 51 The QC procedure depends on the platform used. For spotted arrays, it is difficult to come up with strict guidelines. For Affymetrix arrays, besides the visual aspects, several parameters can be checked, as recently proposed by the 'Tumor Analysis Best Practices Working Group'. 34 All microarray analyses should include some technical replicates leading to a measure of technical reproducibility in order for the researchers to determine whether the individual measurements are reproducible enough. However, replicates of the whole series of samples, as performed in the early times of microarray analyses, are not generally necessary because of the high concordance of the data obtained by experienced researchers. Instead of increasing the number of technical replicates, one should increase the number of biological samples in, for example, two groups that will be compared. By including several biological samples, the influences of biological differences and technical variations are considered, although it will be unclear how much of the variation is owing to technical and as to how much to biological variation (see Figure 3) . However, if one wishes to compare the expression profile of, for example, one sample of a patient with an unknown disease to a group of normal controls, technical duplicates or triplicates of the patient's sample should be made, ideally beginning with the processing of the sample. In this regard, the use of spike-in-RNA controls (corresponding to known amounts of RNA) can also be helpful, as well as tools generated by the External RNA Controls Consortium (ERCC), that is, providing external RNA. 52 In general, and especially for pathway analyses, genes of interest have to be validated using an alternative technique, for example, quantitative RT-PCR.
Biostatistics for data analysis
Various software packages exist to help the investigators mine the enormous amount of information generated by microarray experiments. Commonly used techniques are statistical significance analysis with parametric and non-parametric tests (e.g. t-test, analysis of variance (ANOVA), significance analysis of microarrays (SAM) 53, 54 ), with correction for multiple testing, a variety of further classification methods (e.g. principal component analysis) and different types of cluster analysis (e.g. hierarchical clustering, K-means). 55 Various visualization tools may help to obtain a better overview of the results of analysis, and mapping of genes to molecular and metabolic pathways will help to identify biologically relevant findings. It is beyond the scope of this article to discuss these bioinformatical tools in detail (an overview is given by Allison et al.
56
). We have listed several packages, both commercial and freely available in Table 1 . We highly recommend clinical and biological researchers to consult with a biostatistician even before performing the array experiment to formulate specific questions of the study, to define requirements and to address several issues of data analysis strategies. It should be noted that the same raw microarray data analyzed by different bioinformatical methods can yield very different results, especially for low expressed genes. As these methods differ in the statistical algorithms used to analyze the data, this is not surprising, but is an important aspect to consider. It also goes without saying that the same analysis method should be used throughout a study to compare various data sets.
Biostatistics are essential in understanding the results of array experiments and should be used as transparently as possible, to avoid misleading readers who are not experts in this field. For instance, a list of differentially expressed genes that constitute a signature profile should be accompanied by a false discovery rate (FDR) 58 or a P-value corrected for multiple testing to give an idea of how significant the findings actually are. To illustrate this further, a signature profile with an FDR of, for example, 50% Examples of biological and technical replicates and their influence on differential expression by microarray analyses. Experiments were performed using spotted cDNA microarrays as described recently. 18 The correlation of relative gene expression values of two microarray experiments, respectively, are shown for (a) two biological replicates (mononuclear bone marrow cells (BM MNC) of two healthy controls); (b) two biological replicates of one cell line that was split, then cultured under the same conditions up to two different time points and subsequently processed in parallel; and (c) two technical replicates (the amplified RNA of one sample was split and subsequent steps were performed in parallel). The correlation coefficients R 2 are shown. Similar correlation coefficients were observed using the Affymetrix system. 57 would mean that about half the genes in the signature are selected by chance, and it is not possible to know without independent validation studies which genes these are. This may in some cases still yield important information, but in most cases this is a very high error rate and FDR should be much lower (e.g. in the 10% range). Concerning the individual genes, the reader will realize that further experiments are necessary to identify the true positive ones.
All relevant information necessary for proper interpretation of the experiment and bioinformatic analysis must be included in publications. Array data uploaded into public databases should be raw data as far as possible. Uploading of, for example, Affymetrix GeneChip s Operating Software (GCOS) expression estimates should be accompanied by cell intensity (CEL) files to allow independent data analysis of the raw data. As pointed out above, the data should be presented according to MIAME guidelines and include information about the scaling factor. Further, the description of bioinformatic analysis should document used software packages and algorithms, indication of statistical significance like P-values or FDR of gene lists and handling of outliers and missing values. If possible, the robustness of the results should be tested by means of bootstrapping or leave-one-out cross-validation tests.
Concluding remarks
The exchange of knowledge and experience of technical aspects of microarray analyses between the three networks, that is, I-BFM-SG, the German Competence Network 'Acute and Chronic Leukemias' and the European LeukemiaNet, deeply involved in gene expression profiling in Europe has led to the formulation of these guidelines that can be summarized as follows:
1. Samples within a study should be treated as identically as possible. The technical variations should be kept to a minimum and should be documented. 2. The same anticoagulant should be used throughout the study. 3. Bone marrow and peripheral blood samples should best be processed within 24 h of collection and the time until processing should be annotated. 4. For storage of samples, mononuclear cells can be frozen, preferentially stepwise in a density below 20 Â 10 6 cells/ml, and should be thawed as quickly as possible, at 371C. However, do not mix fresh and frozen samples in one experiment (for reasons of consistency). 5. Ficoll density purification is preferred over whole blood or bone marrow and erythrocyte lysis procedures. 6. Purification is required for pathway analyses, if tumor loads are below 90%. For classification of large series of samples, usage of mononuclear cells from samples with a lower tumor load is acceptable; however, the tumor load of the samples needs to be annotated. 7. TRIzol and RNeasy can be used for RNA extraction.
However, keep to one method for one experiment. 8. Only RNA samples with a 260/280 ratio of 41.8, measured under identical pH and ionic strength, and a Bioanalyzer profile indicating no major degradation and clear 18S and 28S rRNA peaks should be used. Objective RNA quality metrics should be reported. 9. As it is usually not a problem to obtain 42 mg RNA from leukemia samples, additional amplification can often be avoided. If amplification is applied, the same chemistry should be used for all samples and quantitative RT-PCR validation should be performed from non-amplified RNA to test for amplification bias. 10.Labeling, hybridization and washing should be performed according to well-documented protocols, for instance, those supplied by the manufacturer. Again, the same methods should be used throughout the study. 11.Array images should be visually checked for quality (bubbles, scratches, grid alignment). 12.Data handling and data analysis should follow the MIAME guidelines. Scaling factor and other biostatistical parameters of array quality should be recorded (noise, background, quality of housekeeping genes, percentage of genes present). 13.In microarray series, one should check for outliers and ignore those samples, for example, with disparate scaling factors, reduced present calls o25% or high background. 14.Array data uploaded into public databases should be raw data as far as possible. Uploading of, for example, GCOS expression estimates should be accompanied by CEL files to allow independent data analysis of the raw data.
We have here confined ourselves to microarray analyses of leukemias, but many of these requirements apply to lymphomas or other clinical samples, including solid tumors. Guidelines for microarray gene expression analyses in leukemia FJT Staal et al
